Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical
UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...
HKG: 3692
Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment
The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...
Hansoh Pharmaceutical Gets NMPA Approval for HS-10518 Clinical Study in Endometriosis Pain
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...
Biocytogen and Hansoh Enter Antibody Collaboration and Licensing Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license...
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...
Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...
EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data
US-based EQRx Inc. (Nasdaq: EQRX), a biopharma originally established with the aim of “radically” disrupting...
Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...
Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...
Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...
Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...